BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38544687)

  • 21. Risk stratification in patients with anaplastic thyroid carcinoma: role of age.
    Wang M; Wei T; Gong R; Zhu J; Li Z
    Endocrine; 2022 Aug; 77(2):305-318. PubMed ID: 35608773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
    Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
    J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.
    Wong KS; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Barletta JA
    Endocr Pathol; 2020 Sep; 31(3):283-290. PubMed ID: 32445173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poorly differentiated and anaplastic thyroid cancer.
    Patel KN; Shaha AR
    Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients.
    Kong N; Xu Q; Zhang Z; Cui A; Tan S; Bai N
    Front Endocrinol (Lausanne); 2021; 12():704596. PubMed ID: 34385977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
    Wächter S; Di Fazio P; Maurer E; Manoharan J; Keber C; Pfestroff A; Librizzi D; Bartsch DK; Luster M; Eilsberger F
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and prognostic value of preoperative systemic inflammatory markers in anaplastic thyroid cancer.
    Zhang L; Luo H; Wang L; Liu Y; Rui S; Wu Z; Wei T; Gong R; Li Z; Zhu J
    J Surg Oncol; 2020 Oct; 122(5):897-905. PubMed ID: 32596828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
    Fan YL; Li XQ
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
    Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
    In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
    Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
    Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
    Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
    Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
    Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
    Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA
    Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568
    [No Abstract]   [Full Text] [Related]  

  • 38. Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients.
    Walczyk A; Kopczyński J; Gąsior-Perczak D; Pałyga I; Kowalik A; Chrapek M; Hejnold M; Góźdź S; Kowalska A
    PLoS One; 2020; 15(2):e0229264. PubMed ID: 32092093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
    Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
    Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
    [No Abstract]   [Full Text] [Related]  

  • 40. Contrast-enhanced CT-based Radiomics for the Differentiation of Anaplastic or Poorly Differentiated Thyroid Carcinoma from Differentiated Thyroid Carcinoma: A Pilot Study.
    Moon J; Lee JH; Roh J; Lee DH; Ha EJ
    Sci Rep; 2023 Mar; 13(1):4562. PubMed ID: 36941287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.